Bridging functional and structural cardiotoxicity assays using human embryonic stem cell-derived cardiomyocytes for a more comprehensive risk assessment

Toxicological Sciences

Volumn 148, Issue 1, 2015, Pages 241-260

  Clements, Mike ^a   Millar, Val ^a   Williams, Angela S ^a   Kalinka, Sian ^a  

^a GE Healthcare Life Sciences   (United Kingdom)

Author keywords

cardiomyocyte; Cardiotoxicity; drug discovery and development; hESC CM; in vitro; stem cells

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; AMIODARONE; ASTEMIZOLE; AXITINIB; BEPRIDIL; DOXORUBICIN; MEXILETINE; ROSIGLITAZONE; SIBUTRAMINE; SUNITINIB; VERAPAMIL; ZIDOVUDINE; CARDIOTOXIN; FLUORESCENT DYE; NEW DRUG;

ACTION POTENTIAL DURATION; ARTICLE; ASSAY; CARDIOTOXICITY; CELL ADHESION; CELL CULTURE; CELL MOTION; CELL POPULATION; CELLS; CLINICAL OBSERVATION; CONTENT ANALYSIS; CONTROLLED STUDY; DRUG DEVELOPMENT; ECG ABNORMALITY; ELECTROPHYSIOLOGY; EMBRYONIC STEM CELL; EXCITATION CONTRACTION COUPLING; HEART MUSCLE CELL; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IN VITRO STUDY; RISK ASSESSMENT; CALCIUM SIGNALING; CARDIAC MUSCLE CELL; CELL SURVIVAL; CHEMISTRY; CRYOPRESERVATION; CYTOLOGY; DRUG EFFECTS; DRUG RECALL; FLUORESCENCE MICROSCOPY; HIGH THROUGHPUT SCREENING; HUMAN EMBRYONIC STEM CELL; IMAGE PROCESSING; IMPEDANCE; METABOLISM; MITOCHONDRIAL DYNAMICS; NUCLEAR SIZE; PRECLINICAL STUDY; PROCEDURES; TISSUE MICROARRAY; VALIDATION STUDY;

CALCIUM SIGNALING; CARDIOTOXINS; CELL MOVEMENT; CELL NUCLEUS SIZE; CELL SURVIVAL; CELLS, CULTURED; CRYOPRESERVATION; DRUG EVALUATION, PRECLINICAL; DRUGS, INVESTIGATIONAL; ELECTRIC IMPEDANCE; ELECTROPHYSIOLOGICAL PHENOMENA; FLUORESCENT DYES; HIGH-THROUGHPUT SCREENING ASSAYS; HUMAN EMBRYONIC STEM CELLS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MICROSCOPY, FLUORESCENCE; MITOCHONDRIAL DYNAMICS; MYOCYTES, CARDIAC; RISK ASSESSMENT; SAFETY-BASED DRUG WITHDRAWALS; TISSUE ARRAY ANALYSIS;

EID: 84947806157     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfv180     Document Type: Article

References (52)

1. Anonymous. (2011). Zidovudine PK Fact Sheet. Available at: http://www.hiv-druginteractions.org/data/FactSheetImages/FactSheet_DrugID_121.pdf. Accessed July 17, 2015.
2. Anonymous. (2013). Australian Public Assessment Report for Axitinib. Available at: https://www.tga.gov.au/file/736/download. Accessed July 17, 2015.
3. Abassi, Y. A. (2014). The application of xCELLigence RTCA cardio system for safety assessment using stem cell derived cardiomyocytes. Comprehensive In Vitro Proarrhythmia Assay (CiPA) Project, Myocyte Workstream Meeting, March 11, 2014. Available at: https://www.ilsiextra.org/hesi/science/cardiac/cipa/Project%20Documents/March%2010-11,%202014%20Meeting%20Presentations/Yama_Abassi_CIPA_Presentation_Modified.pdf. Accessed May 8, 2015.
4. Abassi, Y. A., Xi, B., Li, N., Ouyang, W., Seiler, A., Watzele, M., Kettenhofen, R., Bohlen, H., Ehlich, A., Kolossov, E., et al. (2012). Dynamic monitoring of beating periodicity of stem cell-derived cardiomyocytes as a predictive tool for preclinical safety assessment. Br. J. Pharmacol. 165, 1424-1441.
5. Abolfathi, Z., Couture, J., Vallée, F., LeBel, M., Tanguay, M., and Masson, E. (2004). A pilot study to evaluate the pharmacokinetics of sibutramine in healthy subjects under fasting and fed conditions. J. Pharm. Pharm. Sci. 12, 345-349.
6. Agarwal, A., Goss, J. A., Cho, A., McCain, M. L., and Parker, K. K. (2013). Microfluidic heart on a chip for higher throughput pharmacological studies. Lab Chip. 13, 3599-3608.
7. Becker, N., Stoelzle, S., Göpel, S., Guinot, D., Mumm, P., Haarmann, C., Malan, D., Bohlen, H., Kossolov, E., Kettenhofen, R., et al. (2013). Minimized cell usage for stem cell-derived and primary cells on an automated patch clamp system. J. Pharmacol. Toxicol. Methods 68, 82-87.
8. Caspi, O., Itzhaki, I., Kehat, I., Gepstein, A., Arbel, G., Huber, I., Satin, J., and Gepstein, L. (2009). In vitro electrophysiological drug testing using human embryonic stem cell derived cardiomyocytes. Stem Cells Dev. 18, 161-172.
9. Cavero, I., and Holzgrefe, H. (2015). CiPA: ongoing testing, future qualification procedure and pending issues. J. Pharmacol. Toxicol. Methods. 76, 27-37.
10. Chu, T. F., Rupnick, M. A., Kerkela, R., Dallabrida, S. M., Zurakowski, D., Nguyen, L., Woulfe, K., Pravda, E., Cassiola, F., Desai, J., et al. (2007). Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370, 2011-2019.
11. Clements, M., and Thomas, N. (2014). High-throughput multiparameter profiling of electrophysiological drug effects in human embryonic stem cell derived cardiomyocytes using multi-electrode arrays. Toxicol. Sci. 140, 445-461.
12. Cohen, J. D., Babiarz, J. E., Abrams, R. M., Guo, L., Kameoka, S., Chiao, E., Taunton, J., and Kolaja, K. L. (2011). Use of human stem cell derived cardiomyocytes to examine sunitinib mediated cardiotoxicity and electrophysiological alterations. Toxicol. Appl. Pharmacol. 257, 74-83.
13. Doerr, L., Thomas, U., Guinot, D. R., Bot, C. T., Stoelzle-Feix, S., Beckler, M., George, M., and Fertig, N. (2015). New easy-to-use hybrid system for extracellular potential and impedance recordings. J. Lab. Autom. 20, 175-88.
14. Doherty, K. R., Wappel, R. L., Talbert, D. R., Trusk, P. B., Moran, D. M., Kramer, J. W., Brown, A. M., Shell, S. A., and Bacus, S. (2013). Multiparameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes. Toxicol. Appl. Pharmacol. 272, 245-255.
15. Drugs@FDA. Avandia Package Insert 2007(a). Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202324Orig1s000PharmR.pdf. Accessed June 26, 2015.
16. Drugs@FDA. Axitinib Pharmacology Review(s) 2012. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202324Orig1s000PharmR.pdf. Accessed May 8, 2015.
17. Drugs@FDA. Doxil Package Insert 2007(b). Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/050718s029lbl.pdf. Accessed May 15, 2015.
18. Drugs@FDA. Sutent Highlights of Prescribing Information 2006. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021938s13s17s18lbl.pdf. Accessed May 14, 2015.
19. Ducroq, J., Mohaou Maati, H., Guilbot, S., Dilly, S., Laemmel, E., Pons-Himbert, C., Faivre, J. F., Bois, P., Stücker, O., and Le Grand, M. (2010). Dexrazoxane protects the heart from acute doxorubicin-induced QT prolongation: a key role for I(Ks). Br. J. Pharmacol. 159, 93-101.
20. Fendyur, A., and Spira, M. E. (2012). Toward on-chip, in-cell recordings from cultured cardiomyocytes by arrays of gold mushroom-shaped microelectrodes. Front. Neuroeng. 5, 21.
21. Gintant, G. (2014). Introduction to CiPA (Comprehensive in vitro ProArrhythmia Assay). CSRC/HESI/SPS/FDA Meeting, December 11, 2014. Available at: http://www.cardiac-safety.org.php53-3.ord1-1.websitetestlink.com/wp-content/uploads/2014/12/3.-CiPA-Overview-Workstreams-Gintant-Rechanneling_Dec-11-2014_FINAL.pdf?_sm_au_=iMVJ8f7r8V4SN335. Accessed May 8, 2015.
22. Guo, L., Coyle, L., Abrams, R. M., Kemper, R., Chiao, E. T., and Kolaja, K. L. (2013). Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicol. Sci. 136, 581-594.
23. Harris, K., Aylott, M., Cui, Y., Louttit, J. B., McMahon, N. C., and Sridhar, A. (2013). Comparison of electrophysiological data from human-induced pluripotent stem cell-derived cardiomyocytes to functional preclinical safety assays. Toxicol. Sci. 134, 412-426.
24. He, H., Tao, H., Xiong, H., Duan, S. Z., McGowan, F. X. Jr, Mortensen, R. M., and Balschi, J. A. (2015). Rosiglitazone causes cardiotoxicity via peroxisome proliferator-activated receptor γ-independent mitochondrial oxidative stress in mouse hearts. Toxicol. Sci. 138, 468-481.
25. Kálai, T., Várbiró, G., Bognár, Z., Pálfi, A., Hantó, K., Bognár, B., Osz, E., Sümegi, B., and Hideg, K. (2005). Synthesis and evaluation of the permeability transition inhibitory characteristics of paramagnetic and diamagnetic amiodarone derivatives. Bioorg. Med. Chem. 13, 2629-2636.
26. Kaneko, T., Nomura, F., Hamada, T., Abe, Y., Takamori, H., Sakakura, T., Takasuna, K., Sanbuissho, A., Hyllner, J., Sartipy, P., et al. (2014). On-chip in vitro cell-network preclinical cardiac toxicity using spatiotemporal human cardiomyocyte measurement on a chip. Sci. Rep. 4, 4670.
27. Kim, K. S., Park, S. J., Lee, H. A., Kim, D. K., and Kim, E. J. (2008). Electrophysiological safety of sibutramine HCl. Hum. Exp. Toxicol. 27, 553-558.
28. Kirsch, G. E., Trepakova, E. S., Brimecombe, J.C., Sidach, S. S., Erickson, H. D., Kochan, M. C., Shyjka, L.M., Lacerda, A. E., and Brown, A. M. (2004). Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern. J. Pharmacol. Toxicol. Methods 50, 93-101.
29. Kramer, J., Obejero-Paz, C. A., Myatt, G., Kuryshev, Y. A., Bruening-Wright, A., Verducci, J. S., and Brown, A. M. (2013). MICE models: superior to the HERG model in predicting Torsade de Pointes. Sci. Rep. 3, 2100.
30. Laverty, H., Benson, C., Cartwright, E., Cross, M., Garland, C., Hammond, T., Holloway, C., McMahon, N., Milligan, J., Park, B., et al. (2011). How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines? Br. J. Pharmacol. 163, 675-693.
31. Lee, S. H., Sung, M. J., Hahn, S. J., Kim, J., Min, G., Jo, S. H., Choe, H., and Choi, B. H. (2012). Blockade of human HERG K+ channels by rosiglitazone, an antidiabetic drug. Arch. Pharm. Res. 35, 1655-1664.
32. Lewis, K. J., Silvester, N. C., Barberini-Jammaers, S., Mason, S. A., Marsh, S. A., Lipka, M., and George, C. H. (2015). A new system for profiling drug-induced calcium signal perturbation in human embryonic stem cell-derived cardiomyocytes. J. Biomol. Screen. 20, 330-340.
33. Li, J., Cousin, C., Tinkler, H., Touhami, J., Petit, V., and Thomas, N. (2014). Profiling of nutrient transporter expression in human stem cell-derived cardiomyocytes exposed to tyrosine kinase inhibitor anticancer drugs using RBD ligands. J. Biomol. Screen. 19, 1185-1192.
34. McKee, E. E., Bentley, A. T., Hatch, M., Gingerich, J., and Susan-Resiga, D. (2004). Phosphorylation of thymidine and AZT in heart mitochondria: elucidation of a novel mechanism of AZT cardiotoxicity. Cardiovasc. Toxicol. 4, 155-167.
35. Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., and Gianni, L. (2004). Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 56, 185-229.
36. Nozaki, Y., Honda, Y., Tsujimoto, S., Watanabe, H., Kunimatsu, T., and Funabashi, H. (2014). Availability of human induced pluripotent stem cell-derived cardiomyocytes in assessment of drug potential for QT prolongation. Toxicol. Appl. Pharmacol. 278, 72-77.
37. Peng, S., Lacerda, A. E., Kirsch, G. E., Brown, A. M., and Bruening-Wright, A. (2010). The action potential and comparative pharmacology of stem cell derived human cardiomyocytes. J. Pharmacol. Methods 61, 277-286.
38. Pointon, A., Abi-Gerges, N., Cross, M. J., and Sidaway, J. E. (2013). Phenotypic profiling of structural cardiotoxins in vitro reveals dependency on multiple mechanisms of toxicity. Toxicol. Sci. 132, 317-326.
39. Rana, P., Anson, B., Engle, S., and Will, Y. (2012). Characterization of human induced pluripotent stem cell-derived cardiomyocytes: bioenergetics and utilization in safety screening. Toxicol. Sci. 130, 117-131.
40. Redfern, W. S., Carlsson, L., Davis, A. S., Lynch, W. G., MacKenzie, I., Palethorpe, S., Siegl, P. K., Strang, I., Sullivan, A. T., Wallis, R., et al. (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res. 58, 32-45.
41. Sager, P. T., Gintant, G., Turner, J. R., Pettit, S., and Stockbridge, N. (2014). Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research Consortium. Am. Heart J. 167, 292-300.
42. Scruggs, E. R., and Dirks Naylor, A. J. (2008). Mechanisms of zidovudine-induced mitochondrial toxicity and myopathy. Pharmacology 2, 83-88.
43. Sirenko, O., Crittenden, C., Callamaras, N., Hesley, J., Chen, Y. W., Funes, C., Rusyn, I., Anson, B., and Cromwell, E. F. (2013). Multiparameter in vitro assessment of compound effects on cardiomyocyte physiology using iPSC cells. J. Biomol. Screen. 18, 39-53.
44. Stevens, J. L., and Baker, T. K. (2009). The future of drug safety testing: expanding the view and narrowing the focus. Drug Discov. Today 14, 162-167.
45. Talbert, D. R., Doherty, K. R., Trusk, P. B., Moran, D. M., Shell, S. A., and Bacus, S. A. (2015). Multi-parameter in vitro screen in human stem cell-derived cardiomyocytes identifies ponatinib-induced structural and functional cardiac toxicity. Toxicol. Sci. 143, 147-155.
46. Thomas, N. (2012). Innovating pre-clinical drug development: towards an integrated approach to investigative toxicology in human models. AIMBE/NIH Summit on Validation and Qualification of New in vitro Tools for the Pre-Clinical Drug Discovery Process. Available at: http://www.nibib.nih.gov/sites/default/files/S2_NThomas_StemCellTechForPreClinicalDrugDiscovery.pdf. Accessed May 8, 2015.
47. Vicente, J., Johannesen, L., Mason, J. W., Crumb, W. J., Pueyo, E., Stockbridge, N., and Strauss, D. G. (2015). Comprehensive T wave morphology assessment in a randomized clinical study of dofetilide, quinidine, ranolazine, and verapamil. J. Am. Heart Assoc. 4, e001615.
48. Voelker, M., and Hammer, M. (2012). Dissolution and pharmacokinetics of a novel micronized aspirin formulation. Inflammopharmacology 20, 225-231.
49. Wegman, E. J. (1990). Hyperdimensional data analysis using parallel coordinates. J. Am. Stat. Assoc. 85, 664-675.
50. Xing, J. Z., Zhu, L., Gabos, S., and Xie, L. (2006). Microelectronic cell sensor assay for detection of cytotoxicity and prediction of acute toxicity. Toxicol. In Vitro 20, 995-1004.
51. Yao, X., Anderson, D. L., Ross, S. A., Lang, D. G., Desai, B. Z., Cooper, D. C., Wheelan, P., McIntyre, M. S., Bergquist, M. L., MacKenzie, K. I., et al. (2008). Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea-pig model. Br. J. Pharmacol. 154, 1446-1456.
52. Zhang, J., Gintant, G., and Pierson, J. (2014). Myocyte approaches to MEA & VSO pilot study & preliminary data. CSRC/HESI/SPS/FDA Meeting, December 11, 2014. Available at: http://www.cardiac-safety.org.php53-3.ord1-1.websitetestlink.com/wpcontent/uploads/2015/01/2.-jiwenzhangMyocyte-pilot-studypresentation-141211-final.LT_.pdf. Accessed May 8, 2015.